{
    "nct_id": "NCT06601296",
    "official_title": "STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK)",
    "inclusion_criteria": "* Patients must have metastatic ccRCC.\n* Patients must have oligoprogression defined as progression in ≤3 lesions.\n* All oligoprogression lesions must be suitable for radiation.\n* Patients must have at least one site of disease that can be safely injected with IMSA101. Lung metastases are excluded.\n* ECOG performance status 0-2.\n* Age ≥ 18 years.\n* Patients must have adequate organ and marrow function within 14 days prior to study entry.\n* All IMDC risk categories are allowed.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with progressive ultracentral/central chest lesions will be excluded",
    "miscellaneous_criteria": ""
}